Prognostic Value of Antigen Expression in Multiple Myeloma: A PETHEMA/GEM Study on 1,265 Patients Enrolled in Four Consecutive Clinical Trials

Leukemia - United Kingdom
doi 10.1038/leu.2017.320
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Prognostic Utility of Serum Free Light Chain Ratios and Heavy-Light Chain Ratios in Multiple Myeloma in Three PETHEMA/GEM Phase III Clinical Trials

PLoS ONE
Multidisciplinary
2018English

Prognostic Value of CD56 Expression in Multiple Myeloma

Research in Oncology
2020English

The Diagnostic and Prognostic Value of Plasma microRNA‑125b‑5p in Patients With Multiple Myeloma

Oncology Letters
Cancer ResearchOncology
2018English

Validation of Prognostic Scoring and Assessment of Clinical Benefit for Patients With Bone Sarcomas Enrolled in Phase I Clinical Trials

Oncotarget
Oncology
2016English

Clinical Characteristics and Prognostic Factors in Multiple Myeloma Patients With Light Chain Deposition Disease

American Journal of Hematology
Hematology
2017English

Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2019English

Prognostic Significance of Upfront Radiation Therapy in Patients With Multiple Myeloma

American Journal of Hematology
Hematology
2019English

Clinical Implications of C-Maf Expression in Plasma Cells From Patients With Multiple Myeloma

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2017English

Low Serum miR-19a Expression as a Novel Poor Prognostic Indicator in Multiple Myeloma

International Journal of Cancer
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy